A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer (NCT04506554)
A Phase II Trial of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
🩺 Plain-English Summary (8th-Grade Level)
Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer (MIBC). Patients with pre-specified tumor mutations and complete clinical response with neoadjuvant therapy will preserve their bladders and go on active surveillance.
Who can join: Review the eligibility criteria below.
Location: UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
- UT Southwestern Medical Center — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Muscle-Invasive Bladder Carcinoma
- Prophylactic Antibiotics in Cystectomy With Diversion — Minneapolis, Minnesota
- Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease — Orlando, Florida
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors — Santa Monica, California
- Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology — Los Angeles, California
- NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment — Vancouver, British Columbia
Explore by condition: All Muscle-Invasive Bladder Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.